A Phase 1b/2 Study of CPI-1205, a Small Molecule
Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer (1205-201), NCT03480646
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
This is a two-arm, open label phase 1b/2 with an oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone.
Following determination of MTD and RP2D will proceed to phase 2. Patients in phase 2 will receive CPI-1205 at the RP2D in combination with either enzalutamide or abiraterone/prednisone.
MORE DETAILS ON THIS TRIAL
17146 / NCT03480646 / Call PM 3-29-2018